Eidogen-Sertanty Licenses Kinase Database to Medisyn Technologies
News Sep 09, 2005
Eidogen-Sertanty, Inc. has announced that they have licensed their Kinase Knowledgebase™ to Medisyn Technologies.
This announcement comes after the significant expansion of the Eidogen Kinase Knowledgebase in July 2005, which now contains over 160,000 SAR data points and over 390,000 kinase compounds mined from scientific literature and patents.
The Kinase Knowledgebase is Eidogen-Sertanty's database of structure-activity relationships (SAR) and chemical synthesis data focused on protein kinases -- one of the therapeutically important classes of drug targets.
Medisyn entered into an annual license agreement of the Kinase Knowledgebase after an initial validation of the data quality.
"We were very pleased with the quality and comprehensiveness of Eidogen-Sertanty's kinase database," said David Land, President of Medisyn.
"Medisyn's value lies in our ability to make drug discovery faster, less expensive and more predictable for biotechnology and pharmaceutical companies.”
“The Kinase Knowledgebase broadens our palette of experimentally characterized compounds, saving preparation time and dollars in the application of our Fast Forward Engineering™ predictive discovery platform.”
“We're optimistic that the data quality will contribute further efficiencies to our drug discovery process."
"We are excited to add Medisyn to our growing customer base,” said Steve Muskal, CEO of Eidogen-Sertanty.
“The fact that early stage platform-based drug discovery companies like Medisyn find value in our kinase database content highlights the universal applicability of our content across small, medium, and large drug discovery organizations."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE